| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ccef2a64e3eda246b408b23ff3cf45c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-999 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0667
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-51 |
| filingDate |
2019-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b00d7a9cad009bfe988a013bbd0b29b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a80a0af3631faf0d67b2d692ca5b5960
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_311e73aa255dfca873704a1ba380d200
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62944e0d1c373596ee61614ace8f69b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb73c7857dbe16ff92946d726ad50f0a |
| publicationDate |
2020-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2020183369-A |
| titleOfInvention |
Pharmaceutical composition used to treat cardiac hypertrophy |
| abstract |
PROBLEM TO BE SOLVED: To provide a pharmaceutical composition containing stem cells and a pharmaceutically acceptable carrier used for the treatment of cardiac hypertrophy. SOLUTION: A pharmaceutical composition containing stem cells obtained by pretreatment and reaction with n-butylidenephthalide is injected distally into the body of a hypertensive patient to reduce the content of superoxide in the myocardium. It is possible to increase the activity of STAT3, increase the content of macrophages M2 that promote the elimination of inflammation, and effectively treat the symptoms of cardiac hypertension due to hypertension. [Selection diagram] FIG. 1A |
| priorityDate |
2019-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |